- Total Do-It-Yourself Portfolios with SUPG:
- Sept2006
- Sanch1
- the kid Portfolio 1
- Appala Narsaih Basic Portfolio
- william
- C. Melsbakas Portfolio 1
- Armen Anooshian Portfolio 1
- Larry Hupp Portfolio 1
- Terry 1
- leoloomie Portfolio 1
- blake235 Portfolio 1
- HAPPINESS & FREEDOM
- hafnerinc
- yle3 Portfolio 1
- wlbtdi Portfolio 1
- uzdarwin Portfolio 1
- eag277rgh Portfolio 1
- xylibris Portfolio 1
- kss007 Portfolio 1
- nughaud Portfolio 1
- jaroslaw Portfolio 1
- Darin's Stocks
- nomi44 Portfolio 1
- ted jube Portfolio 1
- Make Some
- aradhana
- vn1066 Portfolio 1
- ANDY47 Portfolio 1
- juan@mailinator.com Portfolio 1
- MyShiite
- billholbrook Portfolio 1
- alleychatte Portfolio 1
- ASCO is coming...Papers released May 15
- show more
- 65
- ULYSSES JACKSON Portfolio 1
- Howard Armstrong Portfolio 1
- tmcdanne Inc.
- Ray G. Fernandez Portfolio 1
- PeterG Portfolio 1
- stu paltrowitz Portfolio 1
- Lawrence Gatewood Portfolio 1
- billig
- stockjock Portfolio 1
- pass2play Portfolio 1
- No Pain No Gain
- SUPRATRADE-QUANTUM 6
- poop
- odessaus Portfolio 1
- smoking
- Gene Macial's Inside Wall Street Stock Picks
- dsparks9872 Portfolio 1
- Radman44 Speculative
- mikefossen Portfolio 1
- ACrawford Portfolio 1
- JTW
- dvlsrthand Portfolio 1
- massy shok Portfolio 1
- rhowell3173 Portfolio 1
- richardk Portfolio 1
- pharmer
- kubsmoyer Portfolio 1
- shutzen1
- andy50 Portfolio 1
- Monitor Growth 07
- mkpuli Portfolio 1
- PANTERA GROUP 178
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:ddnorman |
Date:06 15 07 |
Good cancer stock |
|
Not yet rated
Rate now:
|
|
By:prabhakarcs |
Date:04 16 07 |
It will be up by $2.00 in 2007. |
|
Not yet rated
Rate now:
|
|
By:John Trevor |
Date:04 15 07 |
Biotechs are gaining traction this year as fund managers discover many with viable products that are still underpriced. One is SuperGen (SUPG ) (SUPG), whose drugs target solid tumors, blood disorders, and hematological malignancies. Now trading at 4.78, SuperGen has inked a pact with Johnson & Johnson (JNJ ) to market its Food & Drug Administration-approved drug Dacogen--for myelodysplastic blood disorder syndrome--outside North America. To start, J&J plans to focus on Europe and Japan. In the U.S., Dacogen is marketed by MGI Pharma (MOGN ), which owns 9% of SuperGen. Dacogen's U.S. 2006 sales totaled $36 million, beating even the company's estimate of $25 million. For 2007, Dacogen sales will hit $120 million, figures Elemer Piros of Rodman & Renshaw, who rates the stock a buy, with a 12-month target of 24. SuperGen's own estimate is a more modest $100 million. Its royalties from MGI will grow as sales expand, so Piros expects MGI to buy SuperGen at some point. Vinny Jindal of ThinkEquity Partners also rates SuperGen a buy, but with a much lower 12-month target of 8. He expects to see an uptick in Dacogen sales in the first quarter. |
|
Rate now:
|
|
By:jpose |
Date:04 11 07 |
artilce |
|
Not yet rated
Rate now:
|
|
Date:03 28 07 |
|
Market potential for lisencing new developements |
|
Not yet rated
Rate now:
|
|
By:rdayle |
Date:03 21 07 |
LIKE THE PRODUCTS IT IS DEVELOPING |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Upgraded by Lazard Capital from Sell to Hold |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |



